周忠江,侯玉清

• 1:南方医科大学附属南方医院心内科

摘要(Abstract)：

<正>纵观冠状动脉介入发展30年,尽管介入器材和介入技术迅猛发展,但再狭窄问题仍未被完全征服。单纯经皮冠状动脉腔内成形术(PTCA)再狭窄高达30%~60%,裸金属支架(BMS)置入术后再狭窄可达30%,药物洗脱支架(DES)置入术后再狭窄仍达5%~10%。为此,人们先后尝试普通球囊再次扩张、血管内放射治疗及再次置入DES,但再狭窄问题仍然困扰着广大介入医师和患者。近年来,药物洗脱球囊(drug eluting ballon,DEB)或称药物涂层球囊(drug coated ballon,DCB)异军突起,在冠状动脉及外周介入领

关键词(KeyWords)： 药物涂层球囊;再狭窄;紫杉醇

Abstract:

Keywords:

基金项目(Foundation): 广东省自然科学基金(S2011010003867)

作者(Author): 周忠江,侯玉清

参考文献(References)：

• [1]Van Den Berg JC,Pedrotti M,Canevascini R,et al.Endovascular treatment of in-stent restenosis using excimer laser angioplasty and drug eluting balloons.J Cardiovasc Surg(Torino),2012,53:215-222.
• [2]Bonaventura K,Sonntag S,Kleber FX.Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons.EuroIntervention,2011,7 Suppl K:K106-111.
• [3]Schnorr B,Speck U,Scheller B.Review of clinical data with Paccocath-coated balloon catheters.Minerva Cardioangiol,2011,59:431-445.
• [4]Sgueglia GA.Innovative approaches to percutaneous bifurcation interventions using drug-eluting balloons.Minerva Cardioangiol,2012,60:531-537.
• [5]Briguori C,Virmani R,Kolodgie F,et al.From bench to bedside:initial experience with the Primus drug-coated balloon catheter.Minerva Cardioangiol,2012,60:507-515.
• [6]Bozsak F,Chomaz JM,Barakat AI.Modeling the transport of drugs eluted from stents:physical phenomena driving drug distribution in the arterial wall.Biomech Model Mechanobiol,2014,[Epub ahead of print].
• [7]W?hrle J.Drug-coated balloons for coronary and peripheral interventional procedures.CurrCardiol Rep,2012,14:635-641.
• [8]Buechel R,Stirnimann A,Zimmer R,et al.Drug-eluting stents and drug-coated balloons in peripheral artery disease.Vasa,2012,41:248-261.
• [9]Scheller B,Hehrlein C,Bocksch W,et al.Treatment of coronary instent restenosis with a paclitaxel-coated balloon catheter.N Engl J Med,2006,355:2113-2124.
• [10]Dhakam S,Jafferani A,Ahmed H,et al.Safety and effi cacy of drugeluting balloons in the treatment of drug-eluting in-stent restenosis:experience of a tertiary care hospital.J Invasive Cardiol,2012,24:335-338.
• [11]Ishikawa K,Aoyama Y,Hirayama H.Management of drug-eluting stent restenosis.J Invasive Cardiol,2012,24:178-182.
• [12]Unverdorben M,Vallbracht C,Cremers B,et al.Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis.Circulation,2009,119:2986-2994.
• [13]Cuculi F,Young M,Beeler R,et al.Good effi cacy of drug-eluting balloons in a mixed population of patients with coronary artery disease.J Invasive Cardiol,2012,24:151-153.
• [14]Bromage DI,Lim JC,Ramcharitar S.New technologies aimed at percutaneous intervention in the small coronary artery.Expert Rev Cardiovasc Ther,2012,10:441-455.
• [15]Ferraresi R,Centola M,Biondi-Zoccai G.Advances in below-theknee drug-eluting balloons.J Cardiovasc Surg,2012,53:205-213.
• [16]Rittger H,Brachmann J,Sinha AM,et al.A randomized,multicenter,single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis:the PEPCAD-DES study.J Am Coll Cardiol,2012,59:1377-1382.
• [17]Bonaventura K,Leber AW,SohnsC,et al.Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease.Clin Res Cardiol,2012,101:573-584.
• [18]Sergie Z,Dangas GD.In-stent restenosis of bifurcation lesions:experience with drug-eluting balloons.Catheter CardiovascInterv,2012,79:397-398.
• [19]付强,苗志林,李占全.药物洗脱球囊的研究进展.中国介入心脏病学杂志,2011,19:111-113.
• [20]Cremers B,Toner JL,Schwartz LB,et al.Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter.Clin Res Cardiol,2012,101:469-476.
• [21]Loh JP,Barbash IM,Waksman R.The current status of drug-coated balloons in percutaneous coronary and peripheral interventions.EuroIntervention,2013,9:979-988.